Market Research Logo

Osteosarcoma - Pipeline Review, H2 2018

Osteosarcoma - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Pipeline Review, H2 2018, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.

Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 22, 8, 1, 23 and 5 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 2, 2, 2 and 4 molecules, respectively.

Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Osteosarcoma - Overview
Osteosarcoma - Therapeutics Development
Osteosarcoma - Therapeutics Assessment
Osteosarcoma - Companies Involved in Therapeutics Development
Osteosarcoma - Drug Profiles
Osteosarcoma - Dormant Projects
Osteosarcoma - Discontinued Products
Osteosarcoma - Product Development Milestones
Appendix
List of Tables
Number of Products under Development for Osteosarcoma, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Target, H2 2018 (Contd..2), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..2), H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Osteosarcoma - Pipeline by Advenchen Laboratories LLC, H2 2018
Osteosarcoma - Pipeline by Amgen Inc, H2 2018
Osteosarcoma - Pipeline by AntiCancer Inc, H2 2018
Osteosarcoma - Pipeline by APEIRON Biologics AG, H2 2018
Osteosarcoma - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2018
Osteosarcoma - Pipeline by Autolus Therapeutics Plc, H2 2018
Osteosarcoma - Pipeline by AVEO Pharmaceuticals Inc, H2 2018
Osteosarcoma - Pipeline by Bayer AG, H2 2018
Osteosarcoma - Pipeline by Bellicum Pharmaceuticals Inc, H2 2018
Osteosarcoma - Pipeline by Boehringer Ingelheim GmbH, H2 2018
Osteosarcoma - Pipeline by Bristol-Myers Squibb Co, H2 2018
Osteosarcoma - Pipeline by Cellectar Biosciences Inc, H2 2018
Osteosarcoma - Pipeline by Cellestia Biotech AG, H2 2018
Osteosarcoma - Pipeline by Cellmid Ltd, H2 2018
Osteosarcoma - Pipeline by CorMedix Inc, H2 2018
Osteosarcoma - Pipeline by Eisai Co Ltd, H2 2018
Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, H2 2018
Osteosarcoma - Pipeline by Endocyte Inc, H2 2018
Osteosarcoma - Pipeline by Exelixis Inc, H2 2018
Osteosarcoma - Pipeline by GlycoMimetics Inc, H2 2018
Osteosarcoma - Pipeline by Intezyne Inc, H2 2018
Osteosarcoma - Pipeline by Iovance Biotherapeutics Inc, H2 2018
Osteosarcoma - Pipeline by Ipsen SA, H2 2018
Osteosarcoma - Pipeline by Isofol Medical AB, H2 2018
Osteosarcoma - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2018
Osteosarcoma - Pipeline by MacroGenics Inc, H2 2018
Osteosarcoma - Pipeline by Mateon Therapeutics Inc, H2 2018
Osteosarcoma - Pipeline by MD Biosciences GmbH, H2 2018
Osteosarcoma - Pipeline by Merck & Co Inc, H2 2018
Osteosarcoma - Pipeline by Merck KGaA, H2 2018
Osteosarcoma - Pipeline by Nektar Therapeutics, H2 2018
Osteosarcoma - Pipeline by Novartis AG, H2 2018
Osteosarcoma - Pipeline by Oncolys BioPharma Inc, H2 2018
Osteosarcoma - Pipeline by Ono Pharmaceutical Co Ltd, H2 2018
Osteosarcoma - Pipeline by Pfizer Inc, H2 2018
Osteosarcoma - Pipeline by Scancell Holdings Plc, H2 2018
Osteosarcoma - Pipeline by Sorrento Therapeutics Inc, H2 2018
Osteosarcoma - Pipeline by Teijin Pharma Ltd, H2 2018
Osteosarcoma - Pipeline by Tyme Technologies Inc, H2 2018
Osteosarcoma - Dormant Projects, H2 2018
Osteosarcoma - Dormant Projects, H2 2018 (Contd..1), H2 2018
Osteosarcoma - Discontinued Products, H2 2018
List of Figures
Number of Products under Development for Osteosarcoma, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report